Furthermore, a phase II clinical trial (NCT04639219) of trastuzumab deruxtecan in 102 patients with solid tumors with HER2-activating mutant cancer showed an objective response rate of 29.4% according to an independent central review. This evidence concerns the gene ERBB2 and cancer.